The potential application for stem cells in regenerative medicine is enormous; however, transplanted cells need to be donor matched in order to avoid rejection by the host immune system.
Immune rejection is mediated by major histocompatibility genes, and ensuring that these genes match is the central tenet of successful organ transplantation.
Universal Cells uses genetic engineering to manipulate histocompatibility genes and create non-immunogenic stem cells that can be used for therapeutic applications.
We have developed proprietary technology that enables the immune evasion of transplantable stem cells by eliminating and/or customizing HLA gene expression, thus allowing researchers and companies to work with a histocompatible, allogeneic, off-the-shelf stem cell product for the regenerative medicine market.
Our patented technology is based on recombinant adeno-associated virus (AAV)-mediated gene targeting, which offers high accuracy and safety, and the best vehicle available for cellular delivery.